Identifcation of immune subtypes of Phneg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib
The clinical outcome of Philadelphia chromosome-negative B cell acute lymphoblastic leukemia (Phneg B-ALL) varies considerably from one person to another after clinical treatment due to lack of targeted therapies and leukemia’s heterogeneity.